Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter pylori to prevent gastric cancer:A markov model

被引:4
作者
Hin-Peng Lee
机构
[1] Department of Community Occupational
[2] National University of Singapore
[3] Singapore 117597
[4] Yong Loo Lin School of Medicine
[5] and Family Medicine
关键词
Cost-effectiveness analysis; Gastric cancer; Helicobacter pylori; 13C-Urea breath test; Serology;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
AIM:To compare the costs and effectiveness of no screening and no eradication therapy, the population- based Helicobacter pylori (H pylori) serology screening with eradication therapy and 13C-Urea breath test (UBT) with eradication therapy. METHODS:A Markov model simulation was carried out in all 237 900 Chinese males with age between 35 and 44 from the perspective of the public healthcare provider in Singapore. The main outcome measures were the costs, number of gastric cancer cases prevented, life years saved, and quality-adjusted life years (QALYs) gained from screening age to death. The uncertainty surrounding the cost-effectiveness ratio was addressed by one-way sensitivity analyses. RESULTS:Compared to no screening, the incremental cost-effectiveness ratio (ICER) was $16 166 per life year saved or $13 571 per QALY gained for the serology screening, and $38 792 per life year saved and $32 525 per QALY gained for the UBT. The ICER was $477 079 per life year saved or $390 337 per QALY gained for the UBT compared to the serology screening. The cost- effectiveness of serology screening over the UBT was robust to most parameters in the model. CONCLUSION:The population-based serologyscreening for H pylori was more cost-effective than the UBT in prevention of gastric cancer in Singapore Chinese males.
引用
收藏
页码:3021 / 3027
页数:7
相关论文
共 7 条
[1]  
Cost-Effectiveness of Population Screening for Helicobacter Pylori in Preventing Gastric Cancer and Peptic Ulcer Disease, Using Simulation[J] . P Roderick.Journal of Medical Screening . 2003 (3)
[2]   Gastric cancer epidemiology and risk factors [J].
Kelley, JR ;
Duggan, JM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (01) :1-9
[3]  
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study[J] . C Gambaro,C Bilardi,P Dulbecco,E Iiritano,P Zentilin,C Mansi,P Usai,S Vigneri,V Savarino.Digestive and Liver Disease . 2003 (11)
[4]   Validation of [13C]urea breath test for Helicobacter pylori using a simple gas chromatograph mass selective detector [J].
Lee, HS ;
Gwee, KA ;
Teng, LY ;
Kang, JY ;
Yeoh, KG ;
Wee, A ;
Chua, BC .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (07) :569-572
[5]  
Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials[J] . Julie Parsonnet,Ryan A Harris,Howard M Hack,Douglas K Owens.The Lancet . 1996 (9021)
[6]  
Association Between Infection With "Helicobacter Pylori" And Risk Of Gastric Cancer: Evidence From A Prospective Investigation[J] . D. Forman,D. G. Newell,F. Fullerton,J. W. G. Yarnell,A. R. Stacey,N. Wald,F. Sitas.BMJ: British Medical Journal . 1991 (6788)
[7]  
Comparison of 5- and 10-year survival rates in operated gastric cancer patients[J] . S. Koga,N. Kaibara,H. Kishimoto,H. Nishidoi,O. Kimura,T. Okamoto,H. Tamura.Langenbecks Archiv für Chirurgie . 1982 (1)